Abstract:
Described are mechanisms and techniques for enabling incremental non-chronological synchronization of namespaces. In an environment, entities must have unique names within a namespace and entities may only refer to entities that actually exist within the namespace. Synchronizing two such namespaces involves providing a mechanism for indicating that an entity has been created because a reference to that entity has been made even though that entity does not yet exist. At such time as the entity is formally created, the indication is removed. Synchronizing two such namespaces also involves providing a mechanism for indicating that an entity's unique name in the namespace has been compromised through the synchronization process.
Abstract:
Method of asymmetrically hydrosilylating substrates using catalysts having a ligand of the compound of the formula (I) wherein R is optionally substituted alkyl, cycloalkyl, aryl or heteroaryl; R′ is hydrogen, optionally substituted lower alkyl; and R″ is hydrogen, halogen, optionally substituted alkyl, hydroxy, amino (e.g., primary, secondary or tertiary), alkenyl; or an enantiomer thereof; or an enantiomeric mixture thereof with a transition metal. Particularly suitable reactions include the asymmetric hydrosilylation of ketones.
Abstract:
The present invention provides bipyrimidinyl diphosphine compounds of the formula wherein R is optionally substituted alkyl, cycloalkyl, aryl or heteroaryl; R′ and R″ are independently optionally substituted alkyl, cycloalkyl, aryl or heteroaryl; or an enantiomer thereof; or an enantiomeric mixture thereof. The compounds of the formula (I) are chiral atropisomeric bipyrimidinyl diphosphine compounds and, thus, may be employed as ligands to generate chiral transition metal catalysts which may be applied in a variety of asymmetric reactions, e.g., in palladium catalyzed asymmetric allylic substitution reactions. The compounds of the present invention are easily accessible in high enantiomeric purity according to the methods disclosed herein.
Abstract:
Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
Abstract:
The invention provides N-cyclic sulfonamido compounds and salts of Formula I: wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.
Abstract:
Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
Abstract:
A method for identifying one or more image frames (100) from a series (104) of video image frames, in order to print, store or flag the selected frames. The method calculates a gradient value for each image frame in a video shot (102) series, identifies one or more gradient value peaks (324) in a corresponding range of a raw data series (302), and selects the image frames (110) corresponding to the identified gradient value peaks. Two types of frames (202, 206) are identified as being suitable for printing. A first type (202) comprises frames with a high gradient content, where the image is sharply defined. A second type of frame (206) also has good focus, but is representative of periods of relative stillness, or lack of motion between consecutive image frames (100) during the video shot series (104).
Abstract:
The method first segments both images into homogeneous regions (205A) and assigns (207A) semantic labels (such as “sky”, “cloud”, “water”, “foliage” etc) to the homogeneous regions to describe the content of the regions using a probabilistic method. This process also results in each assigned label for a region having an associated probability value expressing the confidence level of the label being correctly assigned The method then computes (108) a distance metric which averages over all corresponding pixels in the two images a value which is the product of a predetermined semantic difference between the assigned labels at the corresponding pixels and a weighting function which is derived from the associated probability values of the labels for each of the corresponding pixels. The semantic difference reflects similarities between the labels. For example, the semantic difference of the label pair “sky” and “foliage” is higher than the semantic difference between the more similar “sky” and “cloud” label pair. The method then compares (110) the distance metric value with a predetermined threshold value in order to determine the similarity of the images.
Abstract:
Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
Abstract:
Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.